3HY Stock Overview
Arix Bioscience plc is a venture capital firm specializing in all stages of growth, seed stage, preclinical and clinical stage assets, startup, early stage, mid venture, late stage, growth capital investments as well as private and public equity. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Arix Bioscience plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£1.61 |
| 52 Week High | UK£1.67 |
| 52 Week Low | UK£1.09 |
| Beta | 1.05 |
| 1 Month Change | 8.05% |
| 3 Month Change | 33.06% |
| 1 Year Change | 28.80% |
| 3 Year Change | -33.47% |
| 5 Year Change | -11.54% |
| Change since IPO | -32.47% |
Recent News & Updates
Recent updates
Shareholder Returns
| 3HY | DE Capital Markets | DE Market | |
|---|---|---|---|
| 7D | -3.6% | -2.4% | -2.0% |
| 1Y | 28.8% | 21.1% | 6.9% |
Return vs Industry: 3HY exceeded the German Capital Markets industry which returned 6.2% over the past year.
Return vs Market: 3HY exceeded the German Market which returned -1.4% over the past year.
Price Volatility
| 3HY volatility | |
|---|---|
| 3HY Average Weekly Movement | 5.9% |
| Capital Markets Industry Average Movement | 4.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 3HY has not had significant price volatility in the past 3 months.
Volatility Over Time: 3HY's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 9 | n/a | arixbioscience.com |
Arix Bioscience plc is a venture capital firm specializing in all stages of growth, seed stage, preclinical and clinical stage assets, startup, early stage, mid venture, late stage, growth capital investments as well as private and public equity. The firm seeks to invest in biotech companies, novel therapeutics, innovative technologies, medical innovation comprising healthcare and life sciences. It seeks to invest globally.
Arix Bioscience plc Fundamentals Summary
| 3HY fundamental statistics | |
|---|---|
| Market cap | €206.79m |
| Earnings (TTM) | €17.52m |
| Revenue (TTM) | €16.59m |
11.8x
P/E Ratio12.5x
P/S RatioIs 3HY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3HY income statement (TTM) | |
|---|---|
| Revenue | UK£14.16m |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£14.16m |
| Other Expenses | -UK£799.00k |
| Earnings | UK£14.96m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.12 |
| Gross Margin | 100.00% |
| Net Profit Margin | 105.64% |
| Debt/Equity Ratio | 0% |
How did 3HY perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/02/12 08:47 |
| End of Day Share Price | 2024/02/12 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Arix Bioscience plc is covered by 9 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Maxim Jacobs | Edison Investment Research |
| Yingheng Chen | Hardman & Co. |
| Dorothea Hill | Hardman & Co. |